Metropolis Healthcare Q4 FY26: Volume-led growth meets a sharper margin profile

Metropolis Healthcare ended Q4 FY26 with a strong set of numbers, supported by steady demand in diagnostics and a clear focus on operational efficiency. On a consolidated basis, Q4 FY26 revenue came in at INR 425 crore, up 23 percent year on year, with EBITDA of INR 108 crore and PAT of INR 51 crore. For the full year, consolidated revenue was INR 1,646 crore, up 24 percent, with EBITDA of INR 401 crore and PAT of INR 191 crore.

The company also reported organic numbers that exclude the recent acquisitions of Core Diagnostics, DAPIC Dehradun, Scientific Pathology Agra, and Ambika Kolhapur. On this basis, Q4 FY26 revenue was INR 392 crore, up 15 percent, with EBITDA of INR 107 crore and PAT of INR 55 crore. FY26 organic revenue was INR 1,510 crore, up 14 percent, with EBITDA of INR 392 crore and PAT of INR 194 crore. Management highlighted that FY26 was a year of compounding, driven by sustained revenue momentum and meaningful margin expansion.

What drove the quarter: volumes, mix, and operating leverage

In Q4 FY26, organic patient volume increased to 3.4 million, up 9 percent year on year, and organic test volume rose to 7.2 million, also up 9 percent. Revenue per patient improved to INR 1,143 and revenue per test to INR 543. Management emphasized that the quarter saw no price increase due to GST reasons, which means growth was supported mainly by demand, improved mix, and execution.

Both channels contributed. Organic B2C revenue was INR 240 crore in Q4 FY26, up 15 percent, and organic B2B revenue was INR 152 crore, also up 15 percent. The company attributed B2C growth to deeper penetration into Tier 3 markets, digital efforts, and network expansion, while B2B growth was supported by service quality and stronger relationships with corporates and hospitals.

Financial summary

Note: Q4 FY25 included one-time expenses of INR 21 crore related to acquisition costs and other items, which affected year-on-year comparisons.

Segment mix continues to shift toward Specialty and TruHealth

Metropolis has been leaning into higher-value testing, and FY26 shows that direction clearly. In the organic business, TruHealth revenue was INR 281 crore in FY26, growing 21 percent year on year, and contributing 19 percent of revenue. Specialty revenue was INR 566 crore, growing 16 percent, and contributing 37 percent of revenue. In Q4 FY26, the organic segment contribution was shown as Routine 17 percent, Semi-special 26 percent, Specialty 37 percent, and TruHealth 20 percent.

The company highlighted a premiumization trend within TruHealth, with premium mix rising to 37 percent, led by vitals, consult and ECG bundles. It also cited expanding radiology-integrated wellness offerings and rural TruHealth offerings, along with increasing contribution from digital channels.

On Specialty, the company pointed to the scaling of Core Diagnostics capabilities across its B2C and B2B network, plus new test launches in areas such as neuro, infectious diseases, oncology, and women and child health. Management also described its genomics platform as a key strategic pillar, anchored by two CAP-accredited genomics labs in Mumbai and Gurugram.

Productivity agenda and network scale are central to the next phase

A key theme in both the investor presentation and the earnings call was throughput-led productivity. The company ended FY26 with 212 clinical labs and a service network of 5,026, with presence across about 750 towns. During FY26, it added 490 centers. Management described a shift away from heavy lab additions and toward better utilization of the existing lab network.

The margin improvement narrative is tied to several operational programs. Management cited lab platform upgrades and standardization, vendor consolidation, barcoding-led inventory discipline, and optimal use of technology in labs. It also said these interventions improved throughput and material productivity, with benefits starting to show in Q4 and expected to strengthen over the next two quarters.

Metropolis 3.0: mini hubs, digital, genomics, and disciplined M&A

The company presented its Metropolis 3.0 strategy around strengthening the core, expanding into adjacencies, bolt-on acquisitions, and sustainability. In the earnings call, management laid out a plan to build 100 mini hubs over the next 3 years. These are intended to go beyond standard collection centers by adding basic radiology and adjacent services. Management estimated capex of roughly INR 30 to 40 lakh per mini hub.

Alongside this, the company plans to add 1,500 more collection centers over 3 years, taking the lab-to-center ratio to 1:35 from 1:24, and targeting a 20 percent improvement in center productivity over 3 years. It also described a tech-enabled D2C vertical as a strategic focus, noting that digital channels have grown meaningfully. Management stated on the call that digital revenue has grown to 25 percent of revenue over the last 3 years, driven by the app, the website, and a customer data platform driven outreach program.

On acquisitions, management stated that integration of DAPIC Dehradun, Scientific Pathology Agra, and Ambika Kolhapur has been completed, while Core Diagnostics integration is expected to be completed by Q1 FY27. It also stated that Core Diagnostics moved from a negative 2 percent EBITDA to a high single digit EBITDA within four quarters, and that the longer-term goal is a 20 percent plus EBITDA profile over three years.

Takeaways

FY26 for Metropolis Healthcare combined consistent volume growth with improving realizations and a stronger mix, resulting in margin expansion. The company is positioning the next phase around better utilization of an expanded network, continued premiumization through TruHealth, deeper specialty and genomics capabilities, and a scaled digital acquisition and engagement engine. Management guidance of 14 to 15 percent revenue CAGR over three years and a 27 to 28 percent sustainable group EBITDA margin sets clear targets, with near-term expectations of 125 to 150 basis points of margin improvement in the coming year.